Want to see GB:DOCS full AI Analyst Report?
DOCS Stock Chart & Stats
78.80 p
2.20 p(2.98%)
At close: 4:00 PM EDT
78.80 p
2.20 p(2.98%)
Day’s Range― - ―
52-Week Range59.15 p - 99.14 p
Previous CloseN/A
Volume588.53K
Average Volume (3M)1.11M
Market Cap
£637.48M
Enterprise Value819.77M
Total Cash (Recent Filing)£180.30M
Total Debt (Recent Filing)£393.50M
Price to Earnings (P/E)26.7
Beta1.48
Next Earnings
Nov 19, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend Yield3.83%
Share Statistics
EPS (TTM)0.02
Shares Outstanding968,027,000
10 Day Avg. Volume986,590
30 Day Avg. Volume1,109,377
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.68
Price to Sales (P/S)0.79
P/FCF Ratio5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£75.00Price Target Upside-4.82% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.05
Revenue Forecast (FY)£787.65M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSolid free cash flow of about 116m and close tracking of operating cash flow indicate the business converts reported earnings into cash effectively. That supports reinvestment, debt service and resilience over the next several quarters, although cash generation has shown some volatility.
Improving LeverageThe sustained reduction in debt-to-equity shows progress in strengthening the capital structure and lowering balance-sheet risk. Improving leverage should provide greater financial flexibility for brand investment, debt servicing and navigating slower demand over the next several quarters.
Operating Margin ReboundThe rebound in operating margin demonstrates that management has restored some operating profitability after the prior-year deterioration. If maintained, stronger EBIT conversion can improve internal funding capacity and help offset weaker revenue growth, even though earnings remain below earlier peaks.
Bears Say
Persistent Revenue DeclineRepeated annual revenue declines point to weakening demand or reduced commercial momentum rather than a single-quarter fluctuation. Continued top-line contraction can limit operating leverage, reduce reinvestment capacity and make it harder for the brand to rebuild earnings over the next several quarters.
Profitability Remains CompressedDespite the operating margin rebound, net profitability remains well below prior levels and gross margin has declined from the mid-60% range. This reduced earnings buffer leaves the company more exposed to ongoing sales pressure and limits the durability of future profit growth.
Elevated Leverage And Lower ReturnsA debt-to-equity ratio above one indicates the balance sheet is manageable but not conservative for a consumer brand facing declining sales. The sharp fall in return on equity also suggests capital is generating less profit, constraining long-term financial efficiency and resilience.
Dr. Martens Plc News
DOCS FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest share price was 59.15 p and its highest was 99.14 p in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is £637.48M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is Nov 19, 2026 which is in 45 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on May 19, 2026. The company reported 0.042 p earnings per share for the quarter, missing the consensus estimate of 0.044 p by -0.002 p.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Overvalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc pays a Semiannually dividend of 1.7 p which represents an annual dividend yield of 3.83%. See more information on Dr. Martens Plc dividends here
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is <0.01.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 968,027,000 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of 0.042 p in its last earnings report, missing expectations of 0.044 p. Following the earnings report the stock price went up 3.267%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in GB:DOCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£75.00 (-4.82% Downside)
£75.00 (-4.82% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.14%
12-Months-Change
Fundamentals
Return on Equity
3.83%
Trailing 12-Months
Asset Growth
-1.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dr. Martens Plc
Dr. Martens plc is a global footwear enterprise that handles the entire process of conceiving, crafting, sourcing materials for, marketing, selling, and distributing its products. The company boasts a significant international presence, serving customers across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its extensive product range includes classic 'Originals' footwear, contemporary 'fusion' styles, children's shoes, and casual designs, alongside various accessories. All merchandise is offered exclusively under the renowned Dr. Martens brand. Established in 1945, Dr. Martens plc maintains its corporate headquarters in London, United Kingdom.
DOCS Stock 12 Month Forecast
Average Price Target
75.00 p
▼(-4.82% Downside)